Demographics and comorbidities by drug
| Metformin | Orlistat | |
| n (total, % GP-initiated) | 44 (27%) | 55 (89%) |
| Female (n, %) | 40 (91%) | 46 (84%) |
| BMI (mean kg/m2, SD) | 35.9 (6.1) | 37.6 (6.5) |
| zBMI (mean, SD) | 3.2 (0.7) | 3.2 (0.6) |
| Median age (range) | 15.7 (6.5–19.2) | 17.3 (13.8–18.8) |
| <12 years (n) | 5 | 0 |
| 12–15.9 years (n) | 19 | 9 |
| 16–17.9 years (n) | 16 | 29 |
| ≥18 years (n) | 4 | 17 |
| Comorbidities (n,%) | ||
| Hypertension | 1 (2%) | 0 |
| Hyperinsulinism/insulin resistance | 13 (30%) | 0 |
| Type 2 diabetes | 0 | 3 (5%) |
| Dyslipidaemia | 1 (2%) | 3 (5%) |
| Emotional distress | 12 (27%) | 17 (31%) |
| Sleep apnoea | 0 | 1 (2%) |
| Polycystic ovarian syndrome | 32 (73%) | 6 (11%) |
| Orthopaedic issues | 3 (7%) | 3 (5%) |
| Pervasive developmental disorder | 3 (7%) | 0 |
| Hypothyroidism | 1 (2%) | 3 (5%) |
BMI, body mass index;